![Leigh Revers](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Leigh Revers
Nessuna posizione attualmente
Profilo
Leigh Revers is the founder of Molecular Templates, Inc. which was founded in 2000.
Dr. Revers held the title of Vice President-Research & Development at Molecular Templates, Inc. from 2009 to 2010.
Dr. Revers also founded Molecular Templates, Inc. in 2000.
Dr. Revers's former job was as a Principal at Hospital for Sick Children Foundation.
Dr. Revers received a doctorate degree from the University of Oxford.
Precedenti posizioni note di Leigh Revers
Società | Posizione | Fine |
---|---|---|
Hospital for Sick Children Foundation | Corporate Officer/Principal | - |
MOLECULAR TEMPLATES, INC. | Fondatore | - |
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Fondatore | - |
Formazione di Leigh Revers
University of Oxford | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Aziende private | 2 |
---|---|
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
Hospital for Sick Children Foundation | Miscellaneous |
- Borsa valori
- Insiders
- Leigh Revers